{"verbs": [{"verb": "presents", "description": "[ARG0: pfizer] [V: presents] [ARG1: overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe] today announced detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the study there was a numerical improvement in os of nearly seven months with ibrance plus fulvestrant compared to placebo plus fulvestrant although this difference did not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany", "tags": ["B-ARG0", "B-V", "B-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "announced", "description": "[ARG0: pfizer] presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe [ARGM-TMP: today] [V: announced] [ARG1: detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the study there was a numerical improvement in os of nearly seven months with ibrance plus fulvestrant compared to placebo plus fulvestrant although this difference did not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany]", "tags": ["B-ARG0", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ARGM-TMP", "B-V", "B-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1"]}, {"verb": "evaluated", "description": "pfizer presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe today announced detailed overall survival os data from [ARG0: the paloma-3 trial] [R-ARG0: which] [V: evaluated] [ARG1: ibrance \u00ae palbociclib] [ARGM-ADV: in combination with fulvestrant] [ARGM-ADV: compared to placebo plus fulvestrant] in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic [ARGM-PRD: breast cancer] whose disease progressed on or after prior endocrine therapy in the study there was a numerical improvement in os of nearly seven months with ibrance plus fulvestrant compared to placebo plus fulvestrant although this difference did not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ARG0", "I-ARG0", "I-ARG0", "B-R-ARG0", "B-V", "B-ARG1", "I-ARG1", "I-ARG1", "B-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "B-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ARGM-PRD", "I-ARGM-PRD", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "compared", "description": "pfizer presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe today announced detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant [V: compared] [ARG2: to placebo plus fulvestrant] in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the study there was a numerical improvement in os of nearly seven months with ibrance plus fulvestrant compared to placebo plus fulvestrant although this difference did not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-V", "B-ARG2", "I-ARG2", "I-ARG2", "I-ARG2", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "progressed", "description": "pfizer presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe today announced detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in [ARG1: women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer] [R-ARG1: whose disease] [V: progressed] [ARGM-TMP: on or after prior endocrine therapy in the study] there was a numerical improvement in os of nearly seven months with ibrance plus fulvestrant compared to placebo plus fulvestrant although this difference did not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "B-R-ARG1", "I-R-ARG1", "B-V", "B-ARGM-TMP", "I-ARGM-TMP", "I-ARGM-TMP", "I-ARGM-TMP", "I-ARGM-TMP", "I-ARGM-TMP", "I-ARGM-TMP", "I-ARGM-TMP", "I-ARGM-TMP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "was", "description": "pfizer presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe today announced detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the study there [V: was] [ARG1: a numerical improvement in os of nearly seven months with ibrance plus fulvestrant] [ARGM-ADV: compared to placebo plus fulvestrant] [ARGM-ADV: although this difference did not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany]", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-V", "B-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "B-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "B-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV", "I-ARGM-ADV"]}, {"verb": "compared", "description": "pfizer presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe today announced detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the study there was a numerical improvement in os of nearly seven months with [ARG1: ibrance plus fulvestrant] [V: compared] [ARG2: to placebo plus fulvestrant] although this difference did not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ARG1", "I-ARG1", "I-ARG1", "B-V", "B-ARG2", "I-ARG2", "I-ARG2", "I-ARG2", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "did", "description": "pfizer presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe today announced detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the study there was a numerical improvement in os of nearly seven months with ibrance plus fulvestrant compared to placebo plus fulvestrant although this difference [V: did] not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-V", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "reach", "description": "pfizer presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe today announced detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the study there was a numerical improvement in os of nearly seven months with ibrance plus fulvestrant compared to placebo plus fulvestrant although [ARG0: this difference] did [ARGM-NEG: not] [V: reach] [ARG1: the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis] twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ARG0", "I-ARG0", "O", "B-ARGM-NEG", "B-V", "B-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "inc", "description": "pfizer presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe today announced detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the study there was a numerical improvement in os of nearly seven months with ibrance plus fulvestrant compared to placebo plus fulvestrant although this difference did not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer [V: inc] her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-V", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "neutropenia", "description": "pfizer presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe today announced detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the study there was a numerical improvement in os of nearly seven months with ibrance plus fulvestrant compared to placebo plus fulvestrant although this difference did not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer [ARGM-MNR: febrile] [V: neutropenia] the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ARGM-MNR", "B-V", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "facebook", "description": "pfizer presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe today announced detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the study there was a numerical improvement in os of nearly seven months with ibrance plus fulvestrant compared to placebo plus fulvestrant although this difference did not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg [V: facebook] leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-V", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "leukopenia", "description": "pfizer presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe today announced detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the study there was a numerical improvement in os of nearly seven months with ibrance plus fulvestrant compared to placebo plus fulvestrant although this difference did not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook [V: leukopenia] european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant professor pfizer wbc u s securities and exchange commission london ibrance germany", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-V", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "pfizer", "description": "pfizer presents overall survival data from paloma-3 trial of ibrance \u00ae palbociclib in patients with hr her2- metastatic breast cancer new york- business wire -oct 20 2018-pfizer inc nyse pfe today announced detailed overall survival os data from the paloma-3 trial which evaluated ibrance \u00ae palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor - positive hr human epidermal growth factor receptor 2-negative her2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the study there was a numerical improvement in os of nearly seven months with ibrance plus fulvestrant compared to placebo plus fulvestrant although this difference did not reach the prespecified threshold for statistical significance median os metastatic breast cancer letrozole cancer sepsis twitter linkedin pfizer oncology the institute of cancer research pfizer inc her2 pfizer global product development fulvestrant nyse nicholas turner thrombocytopenia new york mechanism of action breast cancer febrile neutropenia the new england journal of medicine massimo cristofanilli stomatitis congress u s principal investigator munich mace rothenberg facebook leukopenia european society for medical oncology investigator robert h lurie comprehensive cancer center of northwestern university consultant [ARGM-MNR: professor] [V: pfizer] wbc u s securities and exchange commission london ibrance germany", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ARGM-MNR", "B-V", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}], "words": ["pfizer", "presents", "overall", "survival", "data", "from", "paloma-3", "trial", "of", "ibrance", "\u00ae", "palbociclib", "in", "patients", "with", "hr", "her2-", "metastatic", "breast", "cancer", "new", "york-", "business", "wire", "-oct", "20", "2018-pfizer", "inc", "nyse", "pfe", "today", "announced", "detailed", "overall", "survival", "os", "data", "from", "the", "paloma-3", "trial", "which", "evaluated", "ibrance", "\u00ae", "palbociclib", "in", "combination", "with", "fulvestrant", "compared", "to", "placebo", "plus", "fulvestrant", "in", "women", "with", "hormone", "receptor", "-", "positive", "hr", "human", "epidermal", "growth", "factor", "receptor", "2-negative", "her2-", "metastatic", "breast", "cancer", "whose", "disease", "progressed", "on", "or", "after", "prior", "endocrine", "therapy", "in", "the", "study", "there", "was", "a", "numerical", "improvement", "in", "os", "of", "nearly", "seven", "months", "with", "ibrance", "plus", "fulvestrant", "compared", "to", "placebo", "plus", "fulvestrant", "although", "this", "difference", "did", "not", "reach", "the", "prespecified", "threshold", "for", "statistical", "significance", "median", "os", "metastatic", "breast", "cancer", "letrozole", "cancer", "sepsis", "twitter", "linkedin", "pfizer", "oncology", "the", "institute", "of", "cancer", "research", "pfizer", "inc", "her2", "pfizer", "global", "product", "development", "fulvestrant", "nyse", "nicholas", "turner", "thrombocytopenia", "new", "york", "mechanism", "of", "action", "breast", "cancer", "febrile", "neutropenia", "the", "new", "england", "journal", "of", "medicine", "massimo", "cristofanilli", "stomatitis", "congress", "u", "s", "principal", "investigator", "munich", "mace", "rothenberg", "facebook", "leukopenia", "european", "society", "for", "medical", "oncology", "investigator", "robert", "h", "lurie", "comprehensive", "cancer", "center", "of", "northwestern", "university", "consultant", "professor", "pfizer", "wbc", "u", "s", "securities", "and", "exchange", "commission", "london", "ibrance", "germany"]}